› 7su1

X-ray diffraction
2.53Å resolution

Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.106 in complex with CTLA-4

Released:
DOI: 10.2210/pdb7su1/pdb
PDB entry 7su1 coloured by chain, front view.
PDB entry 7su1 coloured by chain, side view.
PDB entry 7su1 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Improved therapeutic index of an acidic pH-selective antibody.
Lee PS, MacDonald KG, Massi E, Chew PV, Bee C, Perkins P, Chau B, Thudium K, Lohre J, Nandi P, Deyanova EG, Barman I, Gudmundsson O, Dollinger G, Sproul T, Engelhardt JJ, Strop P, Rajpal A
MAbs 14 2024642
PMID: 35192429

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero trimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-210690 (preferred)
Entry contents:
3 distinct polypeptide molecules
Macromolecules (3 distinct):
Fab heavy chain Chain: H
Molecule details ›
Chain: H
Length: 229 amino acids
Theoretical weight: 24.79 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
Fab light chain Chain: L
Molecule details ›
Chain: L
Length: 215 amino acids
Theoretical weight: 23.53 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
Cytotoxic T-lymphocyte protein 4 Chain: C
Molecule details ›
Chain: C
Length: 125 amino acids
Theoretical weight: 13.56 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
UniProt:
  • Canonical: P16410 (Residues: 36-153; Coverage: 63%)
Gene names: CD152, CTLA4
Sequence domains: Immunoglobulin V-set domain

Ligands and Environments

1 bound ligand:
Ligand NAG 1 x NAG
1 modified residue:
Ligand PCA 1 x PCA

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 17-ID
Spacegroup: I4122
Unit cell:
a: 109.66Å b: 109.66Å c: 297.6Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.208 0.206 0.251
Expression system: Homo sapiens

Quick links

Citations

4 review citations

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.
Niu et al. (2022)
3 more